BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
View original at globenewswire.comBioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candi…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
BioNTech developed the first approved mRNA vaccine during COVID-19 pandemic
60% confidencePlan will be additive for both BioNTech and the new company, allowing each organization to drive meaningful impact for patients
60% confidenceOur vision has always been to translate our science into meaningful advances for patients, and we see extraordinary opportunities to unlock the next generation of transformative innovations
60% confidenceUgur and Özlem have established an outstanding track record of innovation over their careers
60% confidenceOver the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline
60% confidenceBioNTech is well positioned to advance its mission and evolve into a commercial multi-product company
60% confidenceBioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end
60% confidenceToday, the company is well positioned to advance its mission and evolve into a commercial multi-product company
60% confidenceOver the course of their careers, Ugur and Özlem have established an outstanding track record of innovation
60% confidenceBioNTech is advancing toward becoming a multi-product company by 2030
60% confidenceBioNTech expects to maximize value for patients and shareholders alike
60% confidence2026 will be the first year in which the Company expects multiple late-stage data readouts across major cancer types
60% confidenceOver the past 18 years, BioNTech has been built from a start-up into a global biopharmaceutical company with a strong and diversified pipeline
60% confidenceCo-founders see extraordinary opportunities to unlock the next generation of transformative innovations
60% confidenceFor us, this is the right time to prepare to hand over the baton
60% confidenceBioNTech expects to maximize value for patients and shareholders with new company structure focusing on distinct strategic priorities
60% confidenceBioNTech expects to have 15 ongoing Phase 3 clinical trials in oncology by year end 2026
60% confidenceSigning of binding agreements expected by end of H1/2026
60% confidenceWe believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients
60% confidenceDuring the COVID-19 pandemic, we expanded beyond oncology to develop the first approved mRNA vaccine, helping to protect people worldwide
60% confidence2026 will be the first year with multiple late-stage data readouts across major cancer types
60% confidence
Citado nestas reportagens da Via News
- AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
- AI-Designed Cancer Drug BD200 Defeats Resistant Tumors, Outperforms Marketed Antibodies →
- AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials →
- Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
- Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →
- FDA Fast-Tracks Lung Cancer Drug as Biotech Sector Logs $430M in Deals →
- Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents →
- Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →
- Vepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug Valuations →